COX-2 - III
Artigo de SD Solomon e col. na Circulation sobre inibição COX-2 e risco cardiovascular.
Article by SD Solomon et al. in Circulation on COX-2 inhibition and cardiovascular risk.
"Celecoxib at 200 or 400 mg twice daily or 400 mg once daily showed a nearly 2-fold?increased cardiovascular risk. The trend for a dose-related increase in cardiovascular events and blood pressure raises the possibility that lower doses or other dose intervals may be associated with less cardiovascular risk."
Ver também/ see also:
Inibição COX-2 e enfarte do miocárdio/ COX-2 inhibition and myocardial infarct.
Anti-inflamatórios após enfarte do miocárdio/ Antiinflammatory drugs after myocardial infarction.
Article by SD Solomon et al. in Circulation on COX-2 inhibition and cardiovascular risk.
"Celecoxib at 200 or 400 mg twice daily or 400 mg once daily showed a nearly 2-fold?increased cardiovascular risk. The trend for a dose-related increase in cardiovascular events and blood pressure raises the possibility that lower doses or other dose intervals may be associated with less cardiovascular risk."
Ver também/ see also:
Inibição COX-2 e enfarte do miocárdio/ COX-2 inhibition and myocardial infarct.
Anti-inflamatórios após enfarte do miocárdio/ Antiinflammatory drugs after myocardial infarction.
